QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,036 signal articles · 529 in last 24h · 103,484 total before filter · latest 27m ago
529last 24h
2510last 7d
482● bullish (7d)
257● bearish (7d)
197publishers
AllMacro243Earnings1479M&A140Regulatory16Product4Analyst29
✕ clear all filtersticker: MRKsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Merck exec says company is discussing use of COVID antiviral drug in Ebola response
Reuters64d agoneutral
Merck exec says company is discussing use of COVID antiviral drug in Ebola response

CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir ‌available as an Ebola treatment to address the widening outbreak in ‌the Democratic Republic of Congo, a senior executive told Reuters. The outbreak, which has so far infected ​a suspected 1,100 people and resulted in 42 deaths, involves a rare strain of the virus called Bundibugyo for which there are no approved vaccines or treatments.

Merck KGaA Q1 Earnings Call Highlights
MarketBeat84d agoneutral
Merck KGaA Q1 Earnings Call Highlights

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

Health Care Roundup: Market Talk
The Wall Street Journal84d agoneutral
Health Care Roundup: Market Talk

Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.

Codexis Q1 Earnings Call Highlights
MarketBeat89d agoneutral
Codexis Q1 Earnings Call Highlights

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million